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Introduction and objectives: Renal function impairment predicts poor survival in heart failure. Attention has re-
cently shifted toworsening renal function, basedmostly on serum creatinine and estimated glomerular ﬁltration
rate. We assessed the prognostic effect of worsening renal function in ambulatory heart failure patients.
Methods: Data from 306 ambulatory patients were abstracted frommedical ﬁles. Worsening renal function was
based on the change in estimated glomerular ﬁltration rate, serum creatinine and ureawithin 6 months of refer-
ral. Prognosis was assessed by the composite endpoint all-cause death or heart failure hospitalization, censored
at 2 years. Hazard ratios were estimated for worsening renal function, adjusted for sex, age, diabetes, New York
Heart Association class, left ventricular systolic dysfunction, medications and baseline renal function.
Results: The agreement among deﬁnitionswas fair, with kappa coefﬁcients generally not surpassing 0.5.Worsen-
ing renal functionwas associatedwith poor outcomewith adjusted hazard ratios (95% conﬁdence interval) of 3.2
(1.8–5.9) for an increase of serum creatinine N0.3 mg/dl; 2.2 (1.3–3.7) for an increase in serum urea N20 mg/dl
and 1.9 (1.1–3.3) for a decrease in estimated glomerular ﬁltration rate N20%, independent of baseline renal
function. The 2-year risk of death/heart failure hospitalization was approximately 50% in patients with an
increase in serum creatinine or in serum urea; this positive predictive value was higher than for decreasing
estimated glomerular ﬁltration rate.
Conclusions: In conclusion, worsening renal function was signiﬁcantly associated with a worse outcome.
Different deﬁnitions identiﬁed different patients at risk and increasing creatinine/urea performed better than
decreasing estimated glomerular ﬁltration rate.© 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
Renal function impairment is common in patients with both acute
and chronic heart failure (HF). A variety of mechanisms can contribute
to a reduction in glomerularﬁltration rate in patients with HF, including
neurohumoral adaptations, reduced renal perfusion, increased renal
venous pressure and right ventricular dysfunction [1,2]. Likewise, both
acute kidney injury and chronic kidney disease may result in cardiac
injury or dysfunction [3,4]. Also, comorbidities such as diabetes
mellitus and drugs used in HF affect renal function [5,6].
Impairment of renal function has long been identiﬁed as a promi-
nent predictor of poor survival and a higher risk of hospitalization in
HF patients [7,8]. Most previous studies have focused on serumd glomerular ﬁltration rate; HF,
ociation;WRF,Worsening renal
demiology, Predictive Medicine
ameda Prof. Hernâni Monteiro,
351 225 513 653.
cine. Published by Elsevier B.V. All rigcreatinine and glomerular ﬁltration rate estimating equations as
markers of renal dysfunction [9,10]. These equations, like the Modiﬁca-
tion of Diet in Renal Disease equation, improve upon serum creatinine
by incorporating known demographic and clinical variables as observed
surrogates for the unmeasured physiological factors other than glomer-
ular ﬁltration rate that affects the serum creatinine concentration, such
as generation and tubular secretion [11]. However, there is growing
evidence that other blood markers of renal dysfunction, such as serum
urea,may be superior to creatininewhen it comes to predicting progno-
sis in patients with HF [12–14]. Blood urea concentration reﬂects a con-
stellation of renal dysfunction, diuretic resistance and cachexia rather
than just the glomerular ﬁltration rate [9].
Attention has recently shifted to the adverse prognosis, reﬂected in
increased length of stay, readmission rate, and short- and long-term
mortality, associated with worsening renal function (WRF) [15–17].
Some authors argue that WRF, deﬁned by an absolute increase in
creatinine, is biased by baseline renal function and that an alternative
deﬁnition should be considered [18].
Our objective was to assess the effect of WRF in ambulatory HF
patients on long-term all-cause death and hospital admission for HF,hts reserved.
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confounders.
2. Methods
2.1. Study design and sample selection
We conducted a retrospective cohort study on ambulatory patients
attending an outpatient clinic especially dedicated to the care of HF
patients, atHospital de São João, a public tertiary care academic hospital.
We screened ﬁles of patients consecutively referred to the clinic from
January 2000 to July 2011 and who had at least 2 appointments
(Fig. 1). Patients were eligible if they had a conﬁrmed diagnosis of HF
according to the European Society of Cardiology criteria [7], with a his-
tory of left ventricular systolic dysfunction, and follow-up at the clinic
for at least the ﬁrst 6 months, excluding patients under renal replace-
ment therapy before the baseline.
From 363 eligible patients, 57 (15.7%) were excluded because there
were no laboratory results available at the hospital's laboratory informa-
tion system in the ﬁrst fourmonths after referral to the clinic (n= 11) or
there were no laboratory results at 6 (±3) months (n = 14) or data on
key variables for analysis were missing (n = 32) (Fig. 1). These 57 pa-
tients did not differ signiﬁcantly from the 306 patients with complete
data for analysis regarding gender (men: 63.2% vs. 63.1%, p = 0.99), age
(mean: 66.9 vs. 67.1 years, p = 0.98), presence of diabetes mellitus
(40.4% vs. 37.6%, p = 0.69), estimated glomerular ﬁltration rate (eGFR)
at baseline b60 ml/min (38.8% vs. 45.4%, p = 0.38), serum creatinine
at baseline≥1.5 mg/dl (16.3% vs. 19.0%, p= 0.66), serum urea at base-
line≥60 mg/dl (36.7% vs. 42.8%, p= 0.42) or risk of death or HF hospi-
talization (23% vs. 17% at 1 year and 40% vs. 32% at 2 years, p = 0.25).
The study protocol conforms to the ethical guidelines of the
Declaration of Helsinki and it was approved by the institution's
ethics committee.
2.2. Data extraction
Data were extracted from the patients' clinical ﬁles, by one trained
data extractor, using standardized procedures and a form designed forFig. 1. Study design and sample selection. HF, heart fathis purpose. We used all available data from electronic and paper
ﬁles. For a long time during the study period, it was a standard practice
at the echocardiography laboratory to report only a semi-quantitative
classiﬁcation of systolic dysfunction; severe left ventricular systolic dys-
function is usually considered to correspond to an ejection fraction
below 30% and this cut-offwas used in this studywhen ejection fraction
was available.
We transformed daily angiotensin converting enzyme-inhibitor or
angiotensin II receptor blocker dose into a single variable considering
equivalent doses of lisinopril, assuming the proportion of the target
dose established in clinical trials as the conversion unit (lisinopril
20 mg = captopril 150 mg = enalapril 20 mg = ramipril 5 mg =
trandolapril 4 mg= perindopril 10 mg= fosinopril 20 mg= losartan
100 mg= candesartan 32 mg= valsartan 160 mg).
The primary outcome of interest was all-cause death or hospitaliza-
tion due to HF. For ascertainment of the occurrence of the outcome, we
relied on all data available in the hospitalﬁle, whether from theHF clinic
or other specialties. Any hospitalization, appointment or procedure in
any specialty was considered evidence of being alive. It is a standard
procedure at the clinic to contact patients or next-of-kin to ascertain
vital status when patients miss appointments. In this population, it is
exceptional for patients to be hospitalized in other institutions and,
when this happens, those events are communicated to the clinic
through a copy of the discharge note.
We considered all-cause death as an endpoint due to the difﬁculty in
assuring the quality of classiﬁcation when considering cause-speciﬁc
deaths, particularly in elderly patients. For hospitalizations, the clinical
diagnosis at the discharge note was considered.2.3. Criteria to deﬁne worsening renal function
Three laboratory parameterswere used: anestimate of the glomerular
ﬁltration rate based on theModiﬁcation of Diet in Renal Disease equation,
serum creatinine and serum urea. Each parameter was categorized ac-
cording to the change in the parameter's value frombaseline to 6 months
surpassing a 20% decrease of the baseline value of the eGFR or an absolute
increase over 0.3 mg/dl of serum creatinine or 20 mg/dl of urea.ilure; LVSD, left ventricular systolic dysfunction.
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We used survival analysis to estimate hospitalization-free survival
after the 6 month visit and its association with WRF indicators. Data
was censored at 2 years. The median follow-up of censored patients
was 730 days and 75% of patients were followed for more than 1 year.
Kaplan–Meier survival estimates were compared among categories of
WRF and are represented graphically. Cox proportional hazards regres-
sion models were used to quantify the association between each tested
WRFmeasure and the outcome. Covariates included in themultivariate
models were decided a priori based on the previous knowledge: sex,
age, diabetes mellitus, New York Heart Association (NYHA) class at
6 months, daily furosemide dose at 6 months, daily angiotensin conver-
sion enzyme inhibitor/angiotensin II receptor blocker dose, beta-
blocker use at 6 months and severe (versus mild–moderate) left ven-
tricular systolic dysfunction. Prognosis-modifying variables that may
change over time, such as NYHA class and therapy, were considered in
the analysis as their value at 6 months since this was the baseline
point to quantify prognosis.
For all analyses, a p value below0.05was considered statistically sig-
niﬁcant. A sample size calculation was not done a priori because the
study was not designed on purpose for this objective. A power calcula-
tion showed that, for the number of unexposed (no worsening renal
function) and exposed (worsening renal function) patients analyzed,
and considering the 2-year risk of the primary endpoint observed
among unexposed patients (20 to 30%), the statistical power to detect
a relative risk of 2 as signiﬁcant was N94% for deﬁnitions based on a 6-
month variation of eGFR (decrease 20%), creatinine (increase 0.3 mg/dl)
and urea (increase 20 mg/dl). Analyses were run in Stata version 11.1
for Windows (StataCorp LP, College Station, TX).3. Results
3.1. Baseline characteristics
Baseline patient characteristics by status of WRF are summarized in
Table 2. Themean age of patients was 67.0± 13.6 years and 63.1%were
male. Most had severe left ventricular systolic dysfunction (66.0%), al-
though 89.3% were in class I/II NYHA. Most patients were taking angio-
tensin converting enzyme inhibitors/angiotensin II receptor blockers
(94.4%; 35.6% on target dose) and beta-blockers (88.6%) at 6 months.
All were taking loop diuretics and 38.6% were under spironolactone.
The mean eGFR was 63.2 ± 21.5 ml/min/1.73 m2. In our study sample,
there were 66 patients (21.6%) and 4 patients (1.3%) with hospitaliza-
tion due to heart failure within one month before the starting point
and the 6-month observation point, respectively. (See Table 1.)
PatientswithWRF,whatever deﬁnition considered,weremore often
female and diabetic, although the difference in the prevalence of diabe-
tes only reached statistical signiﬁcance for increasing serum creatinine;
patients with an increase in urea of at least 20 mg/dl were older and
under higher dose of loop diuretics, whereas those with increasing
serum creatinine or decreasing eGFR were medicated with a higher
dose of renin–angiotensin system inhibitors.Table 1
Deﬁnitions of worsening renal function.
6-month variation
eGFR (MDRD) ↓ 20% of the baseline value
Serum creatinine ↑ 0.3 mg/dl (absolute)
Serum urea ↑ 20 mg/dl (absolute)
eGFR — estimated glomerular ﬁltration rate; MDRD — Modiﬁcation of Diet in Renal
Disease.3.2. WRF incidence
A drop in eGFR bymore than 20% from baseline occurred in 18.0% of
the patients. An increase of serum creatinine bymore than 0.3 mg/dl af-
fected 15.7% of patients, whereas an increase in urea by more than
20 mg/dl was observed in 17.7% of patients (Table 3).
When using the different deﬁnitions, different patients were identi-
ﬁed as having WRF, with kappa coefﬁcients for the concordance not
surpassing 0.5, except between the 6-month variation in eGFR (N20%)
and in serum creatinine (N0.3 mg/dl) which was k = 0.8.
3.3. WRF and outcomes
Of the 306patients, 82.9% (95% conﬁdence interval (CI): 77.9–86.8%)
and 68.3% (95% CI: 62.1–73.8%) were alive and free from hospitalization
for HF at 1 and 2 years, respectively.
When analyzing Kaplan–Meier survival estimates (Fig. 2), patients
with WRF, whatever deﬁnition considered, had poorer survival com-
pared to those with improved or stable renal function.
An increase in serum urea by more than 20 mg/dl or an increase in
serum creatinine by more than 0.3 mg/dl at 6 months conferred higher
risk of death or HF hospitalization within 2 years (54.8% and 48.9%, re-
spectively) than 6-month decrease by more than 20% in eGFR (42.1%)
(Table 3).
WRF deﬁned as an increase of serum creatinine by more than
0.3 mg/dl tripled the risk of death/hospitalization (adjusted HR: 3.2,
95% CI: 1.8–5.8), while an increase of serum urea by more than
20 mg/dl or a decrease in eGFR more than 20% doubled it (adjusted
HR: 2.2, 95% CI: 1.3–3.8; 1.8, 95% CI: 1.1–3.2, respectively).
After adjusting for renal function at baseline, the risk of death/
hospitalization conferred by WRF was maintained in all categories of
change in renal function (Table 3). In sensitivity analysis, patients
with HF hospitalization within 1 month preceding the baseline and
the 6-month assessment point were excluded. The estimates of WRF
prognostic role in restricted sample were stronger than those of the
whole sample (Table 3).
4. Discussion
Depending on the deﬁnition used, WRF incidence within 6 months
of referral to the clinic varied from 15.7% (increase by more than
0.3 mg/dl in serum creatinine) to 18.0% (eGFR decrease more than
20% from baseline), with low concordance among the several criteria,
in our HF ambulatory patients. Independently of the deﬁnition used,
WRF had a signiﬁcantly worse survival, with an increased risk of all
cause death and hospital admission for HF after adjusting for age, co-
morbidities, left ventricular systolic dysfunction, NYHA class, medica-
tions and baseline renal function. The association with prognosis was
stronger when deﬁning WRF based on either serum creatinine or urea,
instead of using the eGFR, when stratifying by the cut-offs used in this
study. The 2-year risk of death/HF hospitalization was approximately
50% in patients with an increase in serum creatinine or in serum urea;
this being the highest positive predictive value in terms of HF prognosis.
Although the relationship between WRF and survival in chronic HF
has already been reported in several multi-center studies [5,16,19,20],
our study reinforces this association in ambulatory patients, a popula-
tion less studied. The deﬁnitions we used, based either on eGFR, creati-
nine or urea, were arbitrary but followed previous studies [5,12–14,16,
19,20], which contributes to comparability and supports the generaliz-
ability of its predictive value. Despite the recently proposed new classi-
ﬁcation of cardio-renal syndromes, the precise mechanism by which
impaired baseline renal function and WRF exert adverse prognostic ef-
fects remains unclear [15]. WRF may be a ﬁnal clinical pathway and
that prognostic signiﬁcance may vary by speciﬁc causal mechanism of
renal insult. Various patterns of WRFmay have different prognostic im-
plications and may require different therapeutic approaches. Transient
Table 2
Patient characteristics by status of worsening renal function.
All 6-month variation in eGFR (MDRD) 6-month variation in serum creatinine 6-month variation in serum urea




Decrease or no change
up to 0.3 mg/dl increase
Increase by more
than 0.3 mg/dl
Decrease or no change
up to 20 mg/dl increase
Increase by more
than 20 mg/dl
N 306 251 55 258 48 252 54
Demographic
Age (years), mean ± SD 67.0 ± 13.6 67.0 ± 13.7 67.5 ± 13.3 66.7 ± 13.6 69.2 ± 13.2 66.0 ± 13.6 72.4 ± 12.4c
Female sex, n (%) 113 (36.9) 85 (33.9) 28 (50.9)a 88 (34.1) 25 (52.1)a 86 (34.1) 27 (50.0)a
Medical history
Diabetes mellitus, n (%) 115 (37.6) 89 (35.5) 26 (47.3) 91 (35.3) 24 (50)a 89 (35.3) 26 (48.2)
Hypertension, n (%) 195 (63.7) 160 (63.8) 35 (63.6) 163 (63.2) 32 (66.7) 158 (62.7) 37 (68.5)
Atrial ﬁbrillation, n (%) 128 (41.8) 107 (42.6) 21 (38.2) 110 (42.6) 18 (37.5) 109 (43.3) 19 (35.2)
HF etiology
Ischemic HF, n (%) 131 (42.8) 109 (43.4) 22 (40.0) 110 (42.6) 21 (43.8) 105 (41.7) 26 (48.2)
Medication at 6 months
Loop diuretic dose, n (%)
≤60 mg 131 (42.8) 110 (43.8) 21 (38.2) 117 (45.3) 14 (29.2) 118 (46.8) 13 (24.1)
61–120 mg 133 (43.5) 106 (42.2) 27 (49.1) 106 (41.1) 27 (56.2) 106 (42.1) 27 (50.0)
N120 mg 42 (13.7) 35 (13.9) 7 (12.7) 35 (13.6) 7 (14.6) 28 (11.1) 14 (25.9)c
ACEIs/ARBs dose, n (%)
0 mg 17 (5.6) 16 (6.4) 1 (1.8) 13 (5.0) 4 (8.3) 14 (5.6) 3 (5.6)
2.5–10 mg 180 (58.8) 155 (61.8) 25 (45.5) 162 (62.8) 18 (37.5) 148 (58.7) 32 (59.7)
≥20 mg 109 (35.6) 80 (31.9) 29 (52.7)b 83 (32.1) 26 (54.2)b 90 (35.7) 19 (35.2)
Beta-blocker, n (%) 271 (88.6) 222 (88.5) 49 (89.1) 227 (88.0) 44 (91.7) 225 (89.3) 46 (85.2)
Spironolactone, n (%) 118 (38.6) 96 (38.3) 22 (40.0) 100 (38.8) 18 (37.5) 98 (38.9) 20 (37.0)
Functional status
NYHA class, n (%)
I 110 (36.0) 88 (35.1) 22 (40.0) 90 (34.9) 20 (41.7) 96 (38.1) 14 (25.9)
II 163 (53.3) 133 (53.0) 30 (54.6) 137 (53.1) 26 (54.2) 132 (52.4) 31 (57.4)
III 33 (10.8) 30 (12.0) 3 (5.5) 31 (12.0) 2 (4.2) 24 (9.5) 9 (16.7)
Severe LVSD, n (%) 202 (66.0) 167 (66.5) 35 (63.6) 171 (66.3) 31 (64.6) 164 (65.1) 38 (70.4)
ACEIs/ARBs, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; eGFR— estimated glomerular ﬁltration rate; HF, heart failure; MDRD—Modiﬁcation of Diet in Renal Disease; LVSD, left ventricular systolic dysfunction; NYHA,
New York Heart Association; SD, standard deviation.











Prevalence of categories of change in renal function within 6 months of referral and association with the risk of death or hospital admission for heart failure up to 2 years later.
Prevalence Risk of death or HF
hospitalization
HR (95% CI)
n (%) 2-year risk (%) p-Value Crude Adjusteda Adjustedb Adjustedc
6-month variation in eGFR (MDRD) 0.07
Increase or no change up to 20% decrease 251 (82.0) 29.2 1 1 1 1
Decrease more than 20% of baseline 55 (18.0) 42.1 1.6 (1.0–2.7) 1.8 (1.1–3.2) 1.9 (1.1–3.3) 2.3 (1.1–4.6)
6-month variation in serum creatinine 0.003
Decrease or no change up to 0.3 mg/dl increase 258 (84.3) 28.4 1 1 1 1
Increase by more than 0.3 mg/dl 48 (15.7) 48.9 2.1 (1.3–3.5) 3.2 (1.8–5.8) 3.2 (1.8–5.9) 4.2 (2.1–8.7)
6-month variation in serum urea b0.001
Decrease or no change up to 20 mg/dl increase 252 (82.4) 27.3 1 1 1 1
Increase by more than 20 mg/dl 54 (17.7) 54.8 2.8 (1.7–4.6) 2.2 (1.3–3.8) 2.2 (1.3–3.7) 3.5 (1.8–6.7)
95% CI, 95% conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio; HF, heart failure; MDRD, Modiﬁcation of Diet in Renal Disease.
a Adjusted for sex, age (continuous), diabetes mellitus, New York Heart Association class at 6 months (categorical: I, II, III), daily furosemide dose at 6 months (≤60 mg, 61–120 mg,
N120 mg), daily angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker dose (categorical: 0, 2.5, 5, 10, 20 and N20 mg of lisinopril-equivalent), beta-blocker at 6 months
(no versus yes), and severe left ventricular systolic dysfunction (severe versus less than severe).
b Adjusted additionally for renal function at baseline: baseline eGFR (b vs≥60 ml/min)when assessing the effect of change in eGFR; baseline serum creatinine (b vs≥1.5 mg/dl) when
assessing the effect of change in serum creatinine; baseline serum urea (b vs ≥60 mg/dl) when assessing the effect of change in serum urea.
c Sensitivity analysis: adjusted for all confounders and baseline renal function, after excluding patients with a hospitalization for heart failure decompensation in themonth before the
baseline evaluation and the 6-month evaluation.
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dehydration), associated with successful treatment of congestion, and
may not be associated with poor outcome. Since a possible transient
renal dysfunction associated with heart failure decompensation was
much more likely at the starting point than at 6 months, we expected
that we could have overestimated the number of patients whose renal
function improved over 6 months, leading to an attenuation of the ef-
fect of worsening renal function, which was even stronger after exclud-
ing patients with a recent decompensation. In contrast, persistent WRF
may occur in patients with more severe HF, neurohumoral activation,
and hemodynamic abnormalities, which are associated with a worse
prognosis [21]. It may also limit the use of prognosis-modifying therapy,
like angiotensin-converting enzyme inhibitors, angiotensin receptor
blockers and beta-blockers.
In previous studies, urea performed better than creatinine in
predicting prognosis in patients with HF [9,12,13]. Similarly, in our
study, having an increase in serum urea by more than 20 mg/dl con-
veyed the worst prognosis of all. Urea reﬂects more than just GFR,
being also a marker of renal tubular reabsorption (50% is reabsorbed
in renal tubules), a better measure of intravascular dehydration and di-
uretic resistance than creatinine [9]. Serum urea also rises with in-
creased protein catabolism due to worsening HF, infection or reduced
dietary protein [22].
Urea may be a better prognostic indicator because it incorporates
the cumulative effects of several inﬂuences, including hemodynamic
alterations that result in renal hypoperfusion, and the extent of neuro-
hormonal activation that is closely associated with altered renal
hemodynamics and the progression of left ventricular dysfunction.
In decompensated HF, the activation of the renin–angiotensin–
aldosterone system, increased catecholamine production, and elevated
endothelin levels contribute to renal arteriolar vasoconstriction. The re-
sult is a reduction in renal perfusion pressure with increased sodium
and water reabsorption that produces a parallel increase in urea reab-
sorption. The net result is reduced urea excretion and an elevation in
plasma concentration level that is not solely due to the fall in GFR and
therefore not associated with a proportional rise in serum creatinine
level. Vasopressin also promotes the reabsorption of urea in the distal
nephron, resulting in increased plasma levels [14]. In advanced HF, the
more frequent use of high-dose diuretics and angiotensin-converting
enzyme inhibitor/angiotensin receptor blocker therapy may potentially
contribute to increases in urea. Muscle wasting and cachexia in patients
with advanced HF may also increase urea. This may explain why urea
may serve as a more encompassing biomarker by reﬂecting the interplay
between cardiovascular and renal dysfunctions, serving as a potentialsurrogate for the increasing use of drugs that affect renal function and
for systemic wasting as a result of advancing HF [12].
Absolute increases in creatinine also performedwell. The incidence of
WRFwas lowerwhen using this deﬁnition, with fewer patients identiﬁed
as havingWRF and, consequently, a worse prognosis. These data reﬂect a
higher speciﬁcity of creatinine regarding its prognostic information.
As previously stated, WRF deﬁned by an absolute increase in creati-
nine may be biased by baseline renal function secondary to the expo-
nential relationship between creatinine and renal function. To some
authors, a relative change in eGFR may describe better the physiology
relevant to WRF [18]. Accordingly, we also accounted for absolute vari-
ations and relative changes in eGRF, although their predictive value
regarding prognosis was lower. A possible explanation may result
from the relatively preserved values of renal function at baseline
(mean eGFR 63.2 ± 21.5 ml/min/1.73 m2; only 10% of the patients
with eGFR ≤ 35.9 ml/min/1.73 m2) and higher proportions of patients
in the lowerNYHAclasses (I and II) in our sample. According to previous
studies, all formulas underestimate the true glomerular ﬁltration rate in
the near-normal values of renal function [23,24]. When the estimated
renal function is N65.0 ml/min/1.73 m2 the true renal function is in
fact higher. Also, the bias is increased in all formulas when used in pa-
tients with mild chronic HF [23]. It is possible that in our patients the
true renal function was in fact underestimated, which may have
reﬂected a less severe prognosis when deﬁning WRF according to the
Modiﬁcation of Diet in Renal Disease formula.
The markers of WRF we used are inexpensive, easily accessible and
commonly seen in daily routinemedical practice, making themvaluable
and affordable tools for prognostic evaluation in HF patients. Other po-
tential markers of renal dysfunction, such as serum cystatin-C or Neu-
trophil Gelatinase-associated Lipocalin, were not used. According to
some studies, serum cystatin C is more sensitive in identifying mild re-
ductions in kidney function than serum creatinine alone [25,26], al-
though its levels may be affected by many factors other than GFR [27,
28]. Neutrophil Gelatinase-associated Lipocalin has been tested as an
early recognition marker of acute kidney injury after cardiac surgery
and in patients with acute HF [29,30], although the available evidence
regarding it as a predictor of outcomes in cardiovascular disease is
very limited [31].
4.1. Strengths and limitations
The main strengths of this study are to provide additional informa-
tion regarding the effect of WRF on long-term all-cause death and hos-
pital admission forHF, in ambulatoryHFpatients. Compared to previous
Fig. 2. Kaplan–Meier cumulative hospitalization-free survival estimates according to deﬁnitions of worsening renal function based on the change in eGFR (MDRD), serum creatinine and serum urea. eGFR, estimated glomerular ﬁltration rate; MDRD,
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deﬁnitions of WRF by applying standardized criteria and comparing
them all in the same patients. Also, since WRF is a dynamic concept,
reﬂecting the change in renal function over time, we ﬁxed the period
over which this change was being considered to improve comparability
among patients of the cohort.
The authors acknowledge several limitations in this study. Data were
analyzed only at two deﬁned points during follow-up. Factors that could
affect the renal function in the intervening periods such as hospitaliza-
tions, medications, dehydration, or exposure to intravenous contrast
were not taken into account. Patients who had incomplete data sets at
the baseline or follow-upwere not included in the analysis, potentially in-
troducing bias. Nevertheless, patients excluded from the analysis were
similar to our study sample regarding potential confounders and risk of
death or HF hospitalization, as previously stated, minimizing the concern
with these exclusions. Other cardiorenal markers such as BNP/NT-pro-
BNP measures [32] were not included in the multivariate model as
potential confounders because of their unavailability for a long time in a
large part of the study sample. The retrospective design, avoiding changes
in practice due to study participation, contributes to a closer approxima-
tion to the real-life prognostic performance of these risk markers.
Learning points
• WRF is associated with a clinically relevant worse outcome.
• Serum creatinine and urea represent powerful, inexpensive, simple
and accessible markers of prognosis in ambulatory HF patients.
6. Conclusion
In ambulatory HF patients, WRF was associated with a clinically rel-
evant worse outcome, independently of important confounders. The
most informative WRF deﬁnitions in terms of HF prognosis were
based on an increase in serum creatinine or in serum urea, more than
the decrease in an estimate of glomerular ﬁltration rate. Serum creati-
nine and urea represent powerful, inexpensive, simple and accessible
markers of prognosis.
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